Accession Number: | 0001562180-21-004207 |
Date: | 2021-06-10 |
Issuer: | SAGE THERAPEUTICS, INC. (SAGE) |
Original Submission Date: |
BARRETT ELIZABETH
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 76.09 | 2021-06-10 | deemed execution date | A | 10,000 (a) | 2031-06-10 | common stock 10,000 | $76.09 | 10,000 | direct |
ID | footnote |
---|---|
f1 | the stock option award was issued pursuant to the sage therapeutics, inc. 2014 stock option and incentive plan in accordance with the terms of the amended and restated non-employee director compensation policy. the option will vest in full upon the earlier to occur of june 10, 2022 or the day immediately prior to the 2022 annual meeting of sage's stockholders, subject to continued service as a director on such date. |